Fundz

BioLineRx Ltd. and Hemispherian AS Form Joint Venture to Develop GLIX1 for Treating Glioblastoma.

Sep 29, 2025

Contract Type

partnership

Tel AvivBiotechnologyHealthcareHealth CareTherapeuticsBiopharmaresearch

Description

BioLineRx Ltd. and Hemispherian AS have established a joint venture to develop GLIX1, a first-in-class oral small molecule aimed at the DNA damage response in glioblastoma and other cancers. The FDA has cleared an IND for a Phase 1/2a study expected to start in Q1 2026.

Company Information

Company

BioLineRx Ltd

Location

2 HaMa'ayan Street

Tel Aviv, Tel Aviv District, Israel

About

BioLineRx is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.

Related People

Philip
Likely contact at this company
••••••••@••••••••

See Philip's verified email →

Ella
Likely contact at this company
••••••••@••••••••

See Ella's verified email →

Phil
Senior decision-maker at this company
••••••••@••••••••

See Phil's verified email →

Tsipi
Senior decision-maker at this company
••••••••@••••••••

See Tsipi's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for BioLineRx Ltd's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

BioLineRx Ltd signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.